<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687124</url>
  </required_header>
  <id_info>
    <org_study_id>H-D-2007-0134</org_study_id>
    <nct_id>NCT04687124</nct_id>
  </id_info>
  <brief_title>EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy -</brief_title>
  <official_title>N-3 Fatty Acid EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy - A Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Rikardt Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malnutrition occurs frequently in patients with cancer during and after radiotherapy to the&#xD;
      gastrointestinal (GI) area and can lead to negative outcomes. N-3 fatty acids from fish,&#xD;
      especially eicosapentaenoic acid (EPA) may possess anticachectic properties. The aim of this&#xD;
      study is to investigate the effect of two nutritional interventions; dietary counselling and&#xD;
      an oral nutritional supplement (ONS) containing 2.2 g of the n-3 fatty acid EPA (Forticare®)&#xD;
      or standard care, including dietary counselling and protein supplementation when needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: Outpatients commencing radiotherapy to the GI area due to dissiminated cancer are&#xD;
      randomized to receive dietary counselling and daily fish-oil supplementation over a 5-7 week&#xD;
      period, or standard care. Outcome parameters are measured at baseline (onset of&#xD;
      radiotherapy), week 5, and 12 weeks after commencing radiotherapy, with one additional&#xD;
      measurement of body weight at week 2. Quality of life (QoL) is measured using the EORTC&#xD;
      QLQ-C30 questionnaire. Radiotherapy-related side effects are assessed using a questionnaire&#xD;
      developed specifically for this study. Data from a historical control group collected in a&#xD;
      previous observational study is included in this study to compare incidence of weight loss.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization by sealed envelopes. Stratified for location of cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight (%)</measure>
    <time_frame>6 weeks</time_frame>
    <description>accumulated weight-loss or gain in per cent of the weight measured between baseline, end of treatment and at follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>energy intake (kJ/day) in % of estimated needs</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean of 3 meausrements in the obeservation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>protein intake (g/kg body weight/day) in % of estimated needs</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mean of 3 meausrements in the obeservation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score (EORTC QLQ-C30 version 3.0) points</measure>
    <time_frame>6 weeks</time_frame>
    <description>difference - before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related side-effects (VAS) scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>questionaire before and after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Abdominal Cancer</condition>
  <condition>Radiotherapy; Complications</condition>
  <condition>Weight Loss</condition>
  <condition>Energy Supply</condition>
  <condition>Protein Deficiency</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The departmental usual procedure with the possibility of requiring of a dietician when needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <description>Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)</description>
    <arm_group_label>Fish oil</arm_group_label>
    <other_name>Dietary counseling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>No specified intervention</description>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  referred to radiotherapy for dissminated, abdominal cancer&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  able to understand and comply with the intervention&#xD;
&#xD;
          -  willingness to participate after oral and written conscent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  conditions precluding evaluations of end-points&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  operations planned in the observation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jens R Andersen, MD,MPA</last_name>
    <phone>+4523346654</phone>
    <email>jra@nexs.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Poula Patursson, MSc, RD</last_name>
    <phone>+298 224 112</phone>
    <email>poulapatursson@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens R Andersen</last_name>
      <phone>+45 454523346654</phone>
      <email>jra@nexs.ku.dk</email>
    </contact>
    <contact_backup>
      <last_name>Grith Møller</last_name>
      <phone>+45</phone>
      <email>gmp@nexs.ku.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Jens Rikardt Andersen</investigator_full_name>
    <investigator_title>Sponsor - Investigator</investigator_title>
  </responsible_party>
  <keyword>Malnutrition</keyword>
  <keyword>radiotherapy,</keyword>
  <keyword>oral nutritional supplements</keyword>
  <keyword>fish-oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protein Deficiency</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

